Quantum Genomics (ALQGC) News
Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in...
PARIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...
PARIS, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...
PARIS, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...
PARIS, June 27, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...
PARIS, May 09, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a...
PARIS, May 04, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a...
PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...
Quantum Genomics has equipped itself with new financial means to pursue the development of firibastat and...
Launch of capital increase of approximately €15 million for institutional investors with cancellation of the...
PARIS, March 31, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a...
PARIS, March 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a...
PARIS, March 14, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a...
Quantum Genomics will receive up to $20 M in upfront, development and sales milestone payments as well as...
Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30% royalties on future salesTeva...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads